Abstract
Positron emission tomography (PET) is considered a potentially useful diagnostic tool in the management of a variety of malignancies. It has been used for staging, evaluating recurrent and metastatic disease and tumoral response to neoadjuvant therapy, and providing prognostic information. However, some data are available about its definitive role in the colorectal cancer (CRC) population. In this chapter, the most recent evidence and future perspectives are presented for [18F]fluorodeoxyglucose PET in managing patients with CRC.
| Original language | English (US) |
|---|---|
| Title of host publication | Imaging Atlas of the Pelvic Floor and Anorectal Diseases |
| Publisher | Springer Milan |
| Pages | 143-154 |
| Number of pages | 12 |
| ISBN (Print) | 9788847008083 |
| DOIs | |
| State | Published - 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- General Medicine
Fingerprint
Dive into the research topics of 'The use of PET/PET CT in the management of colorectal cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver